Mr. Philippe Dubuc reports

THERATECHNOLOGIES DRAWS DOWN ON US$20 MILLION SECOND TRANCHE UNDER ITS TERM LOAN FACILITY WITH AFFILIATES OF MARATHON ASSET MANAGEMENT

Theratechnologies Inc. has drawn down on its second tranche of $20-million (U.S.) under its credit agreement dated July 20, 2022, as amended, with certain funds and accounts for which Marathon Asset Management LP acts as investment manager.

The net proceeds of this second tranche, approximately $19.3-million (U.S.), will be used to redeem all of the issued and outstanding $27.5-million (U.S.) 5.75 per cent convertible unsecured senior notes due on June 30, 2023. The remaining balance will be financed from the company's cash on hand.

The notes were issued under a trust indenture dated as of June 19, 2018, by and among Theratechnologies and Computershare Trust Company of Canada.

About Theratechnologies Inc.

Theratechnologies is a biopharmaceutical company focused on the development and commercialization of innovative therapies addressing unmet medical needs.

We seek Safe Harbor.